Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

This phase II trial tests how well vorinostat works in treating patients with prostate-specific membrane antigen (PSMA)-low castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) (mCRPC). Prostate cancer that has not spread to other parts of the body (localized) is typically treated through surgery or radiotherapy, which for many men is curable. Despite definitive local therapy, cancer that has come back after a period of improvement (recurrent) disease develops in 27-53% of men. Often this is detected by measure

Trial Details

NCT ID

NCT06145633

Phase

PHASE2

Sponsor

Fred Hutchinson Cancer Center

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

Biopsy Procedure
Biospecimen Collection
Bone Scan
Computed Tomography
Fludeoxyglucose F-18
Gallium Ga 68 Gozetotide

Locations (sample)

Seattle, Washington, United States|47.60621,-122.33207

Key Eligibility Criteria

Documented histologically confirmed adenocarcinoma of the prostate.
Patient must have evidence of castration resistant prostate cancer as evidenced by PSA progression (per Prostate Cancer Working Group 3 \[PCWG3\] c…
PSMA SUVmean \< 10 as determined by 68Ga-PSMA-11 PET.
Patients must have received a next-generation androgen receptor-signaling inhibitor (e.g. abiraterone, enzalutamide, apalutamide, darolutamide). Th…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →